<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US6037157 - Method for improving pharmacokinetics - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_8a2b04e7bf975d5171d8e4c0b6365c7a/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_8a2b04e7bf975d5171d8e4c0b6365c7a__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Method for improving pharmacokinetics"><meta name="DC.contributor" content="Daniel W. Norbeck" scheme="inventor"><meta name="DC.contributor" content="Dale J. Kempf" scheme="inventor"><meta name="DC.contributor" content="John M. Leonard" scheme="inventor"><meta name="DC.contributor" content="Richard J. Bertz" scheme="inventor"><meta name="DC.contributor" content="Abbott Laboratories" scheme="assignee"><meta name="DC.date" content="1996-6-26" scheme="dateSubmitted"><meta name="DC.description" content="A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase."><meta name="DC.date" content="2000-3-14" scheme="issued"><meta name="DC.relation" content="EP:0691345:A2" scheme="references"><meta name="DC.relation" content="US:5547823" scheme="references"><meta name="DC.relation" content="US:5552558" scheme="references"><meta name="DC.relation" content="US:5674882" scheme="references"><meta name="DC.relation" content="US:5886036" scheme="references"><meta name="DC.relation" content="WO:1995011992:A1" scheme="references"><meta name="DC.relation" content="WO:1995033464:A2" scheme="references"><meta name="DC.relation" content="WO:1996004913:A1" scheme="references"><meta name="citation_reference" content="D, Kempf, et al., 3rd Conf Retro and Opportun Infect (US) Jan. 28 Feb. 1, 1996 p. 79."><meta name="citation_reference" content="D, Kempf, et al., 3rd Conf Retro and Opportun Infect (US) Jan. 28-Feb. 1, 1996 p. 79."><meta name="citation_reference" content="J. Craig, et al., Int. Conf. AIDS 9(1993) PO A25 0602 RO 31 8959, An Inhibitor of HIV Proteinase, Acts Beneficially with Other Antiviral Agents in 2 and 3 Way Combinations In Vitro."><meta name="citation_reference" content="J. Craig, et al., Int. Conf. AIDS 9(1993) PO-A25-0602 RO 31-8959, An Inhibitor of HIV Proteinase, Acts Beneficially with Other Antiviral Agents in 2- and 3-Way Combinations In Vitro."><meta name="citation_reference" content="J. James, AIDS Treatment News, No. 231 Sep. 29, 1995."><meta name="citation_reference" content="S. Vella, Rationale and Experience with Reverse Transcriptase Inhibitors and Protease Inhibitors, Journ of Acquired Immune Def. Syndrome &amp; Humane Retro. 10(Suppl. 1) S58 S61 1995."><meta name="citation_reference" content="S. Vella, Rationale and Experience with Reverse Transcriptase Inhibitors and Protease Inhibitors, Journ of Acquired Immune Def. Syndrome &amp; Humane Retro. 10(Suppl. 1) S58-S61 1995."><meta name="citation_patent_number" content="US:6037157"><meta name="citation_patent_application_number" content="US:08/687,774"><link rel="canonical" href="http://www.google.com/patents/US6037157"/><meta property="og:url" content="http://www.google.com/patents/US6037157"/><meta name="title" content="Patent US6037157 - Method for improving pharmacokinetics"/><meta name="description" content="A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase."/><meta property="og:title" content="Patent US6037157 - Method for improving pharmacokinetics"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("qUXsU8bOJ_XZsQS81oLQBA"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407723702.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("GBR"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("qUXsU8bOJ_XZsQS81oLQBA"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407723702.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("GBR"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us6037157?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US6037157"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=nKdOBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS6037157&amp;usg=AFQjCNGscR4q7a3FEcu50-AHAW8UI94OiA" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US6037157.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US6037157.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US6037157" style="display:none"><span itemprop="description">A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase....</span><span itemprop="url">http://www.google.com/patents/US6037157?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US6037157 - Method for improving pharmacokinetics</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US6037157 - Method for improving pharmacokinetics" title="Patent US6037157 - Method for improving pharmacokinetics"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US6037157 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/687,774</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Mar 14, 2000</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Jun 26, 1996</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Jun 29, 1995</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2224738A1">CA2224738A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2224738C">CA2224738C</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69624136D1">DE69624136D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69624136T2">DE69624136T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69637511D1">DE69637511D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69637511T2">DE69637511T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69637976D1">DE69637976D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0871465A1">EP0871465A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0871465B1">EP0871465B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1210941A2">EP1210941A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1210941A3">EP1210941A3</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1273298A2">EP1273298A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1273298A3">EP1273298A3</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1284140A2">EP1284140A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1284140A3">EP1284140A3</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1284140B1">EP1284140B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1293207A1">EP1293207A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP1293207B1">EP1293207B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP2130534A1">EP2130534A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP2295052A1">EP2295052A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP2295052B1">EP2295052B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6703403">US6703403</a>, </span><span class="patent-bibdata-value"><a href="/patents/US20020039998">US20020039998</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1997001349A1">WO1997001349A1</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08687774, </span><span class="patent-bibdata-value">687774, </span><span class="patent-bibdata-value">US 6037157 A, </span><span class="patent-bibdata-value">US 6037157A, </span><span class="patent-bibdata-value">US-A-6037157, </span><span class="patent-bibdata-value">US6037157 A, </span><span class="patent-bibdata-value">US6037157A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Daniel+W.+Norbeck%22">Daniel W. Norbeck</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Dale+J.+Kempf%22">Dale J. Kempf</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22John+M.+Leonard%22">John M. Leonard</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Richard+J.+Bertz%22">Richard J. Bertz</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Abbott+Laboratories%22">Abbott Laboratories</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US6037157.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6037157.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US6037157.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (8),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (7),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (108),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (61),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (8)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/6037157&usg=AFQjCNGGdy8wZuV8-gWiTaalHu8rt0VIWw">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D6037157&usg=AFQjCNGhZhYK-ypitR0pfKz2sPoDinPYiQ">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D6037157A%26KC%3DA%26FT%3DD&usg=AFQjCNH5SQc7dOYN1nBzGwl5_EQMq6pOFA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT54569616" lang="EN" load-source="patent-office">Method for improving pharmacokinetics</invention-title></span><br><span class="patent-number">US 6037157 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA38044176" lang="EN" load-source="patent-office"> <div class="abstract">A method is disclosed for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(13)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6037157-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6037157-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6037157-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6037157-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6037157-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6037157-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6037157-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6037157-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6037157-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6037157-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6037157-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6037157-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6037157-6.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6037157-6.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6037157-7.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6037157-7.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6037157-8.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6037157-8.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6037157-9.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6037157-9.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6037157-10.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6037157-10.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6037157-11.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6037157-11.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US6037157-12.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US6037157-12.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(18)</span></span></div><div class="patent-text"><div mxw-id="PCLM5535601" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A method for improving the pharmacokinetics of a drug which is metabolized by cytochrome P450 monooxygenase comprising administering to a human in need of such treatment a therapeutically effective amount of a combination of said drug or a pharmaceutically acceptable salt thereof and ritonavir or a pharmaceutically acceptable salt thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol , taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. The method of claim 1 wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG1343.</div>
    </div>
    </div> <div class="claim"> <div num="9" class="claim">
      <div class="claim-text">9. A method for increasing human blood levels of a drug which is metabolized by cytochrome P450 monooxygenase comprising administering to a human in need of such treatment a therapeutically effective amount of a combination of said drug or a pharmaceutically acceptable salt thereof and ritonavir or a pharmaceutically acceptable salt thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of cyclosporine, FK-506, rapamycin, taxol , taxotere, clarithromycin, A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" class="claim">
      <div class="claim-text">11. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629, KNI-272, CGP 53437, CGP 57813 and U-103017.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" class="claim">
      <div class="claim-text">12. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is selected from the group consisting of A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="13" class="claim">
      <div class="claim-text">13. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is saquinavir.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="14" class="claim">
      <div class="claim-text">14. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is VX-478.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="15" class="claim">
      <div class="claim-text">15. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is MK-639.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="16" class="claim">
      <div class="claim-text">16. The method of claim 9 wherein the drug which is metabolized by cytochrome P450 monooxygenase is AG1343.</div>
    </div>
    </div> <div class="claim"> <div num="17" class="claim">
      <div class="claim-text">17. A method for inhibiting cytochrome P450 monooxygenase comprising administering to a human in need thereof an amount of ritonavir or a pharmaceutically acceptable salt thereof effective to inhibit cytochrome P450 monooxygenase.</div>
    </div>
    </div> <div class="claim"> <div num="18" class="claim">
      <div class="claim-text">18. A method for inhibiting cytochrome P450 monooxygenase comprising contacting the cytochrome P450 monooxygenase with an amount of ritonavir or a pharmaceutically acceptable salt thereof effective to inhibit cytochrome P450 monooxygenase.</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES67442583" lang="EN" load-source="patent-office" class="description">
    <p>This application claims the benefit of U.S. Provisional Patent Application No. 60/000,654, filed Jun. 29, 1995 and also claims the benefit of U.S. Provisional Patent Application No. 60/003,849, filed Sep. 15, 1995, both of which are incorporated herein by reference.</p>
    <heading>TECHNICAL FIELD</heading> <p>The present invention relates to a novel composition and a method for improving the pharmacokinetics of drugs which are metabolized by cytochrome P450 monooxygenase. In addition, the present invention relates to a novel composition and a method for inhibiting retroviral proteases and in particular for inhibiting human immunodeficiency virus (HIV) protease and a composition and a method for inhibiting a retroviral infection, in particular an HIV infection</p>
    <heading>BACKGROUND OF THE INVENTION</heading> <p>Infection by the retrovirus known as human immumodeficiency virus (HIV) continues to be a serious human health problem. Methods for treating HIV infections include administering agents which inhibit the activity of viral enzymes which are essential to the life cycle of the virus.</p>
    <p>The genomes of retroviruses encode a protease that is responsible for the proteolytic processing of one or more polyprotein precursors such as the pol and gag gene products. See Wellink, Arch. Virol. 98 1 (1988). Retroviral proteases most commonly process the gag precursor into core proteins, and also process the pol precursor into reverse transcriptase and retroviral protease. Retroviral proteases are known to be sequence specific. See Pearl, Nature 328 482 (1987).</p>
    <p>The correct processing of the precursor polyproteins by the retroviral protease is necessary for the assembly of infectious virions. It has been shown that in vitro mutagenesis that produces protease-defective virus leads to the production of immature core forms which lack infectivity. See Crawford, J. Virol. 53 899 (1985); Katoh, et al., Virology 145 280 (1985). Therefore, retroviral protease inhibition provides an attractive target for antiviral therapy. See Mitsuya, Nature 325 775 (1987).</p>
    <p>It has recently been disclosed that the HIV protease inhibitor ritonavir (also known as ABT-538) is effective in humans for inhibiting an HIV infection.</p>
    <p>It has also been discovered that ritonavir is an inhibitor of the metabolic enzyme cytochrome P450 monooxygenase.</p>
    <p>Some drugs and, in particular, some HIV protease inhibitors are metabolized by cytochrome P450 monooxygenase, leading to unfavorable pharmacokinetics and the need for more frequent and higher doses than are most desirable. Administration of such drugs with an agent that inhibits metabolism by cytochrome P450 monooxygenase will improve the pharmacokinetics (i.e., increase half-life, increase the time to peak plasma concentration, increase blood levels) of the drug.</p>
    <p>It has been discovered that coadministration of ritonavir with a drug which is metabolized by cytochrome P450 monooxygenase, especially the P450 3A4 isozyme, causes an improvement in the pharmacokinetics of such a drug.</p>
    <p>In particular, it has been discovered that coadministration of ritonavir with an HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase causes an unexpected improvement in the pharmacokinetics of such an HIV protease inhibitor.</p>
    <heading>DISCLOSURE OF THE INVENTION</heading> <p>In accordance with the present invention, there is disclosed a method of improving the pharmacokinetics of a drug (or a pharmaceutically acceptable salt thereof) which is metabolized by cytochrome P450 monooxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt thereof. When administered in combination, the two therapeutic agents can be formulated as separate compositions which are administered at the same time or different times, or the two therapeutic agents can be administered as a single composition.</p>
    <p>Drugs which are metabolized by cytochrome P450 monooxygenase and which benefit from coadministration with ritonavir include the immunosuppressants cyclosporine, FK-506 and rapamycin, the chemotherapeutic agents taxol and taxotere, the antibiotic clarithromycin and the HIV protease inhibitors A-77003, A-80987, MK-639, saquinavir, VX-478, AG1343, DMP-323, XM-450, BILA 2011 BS, BILA 1096 BS, BILA 2185 BS, BMS 186,318, LB71262, SC-52151, SC-629 (N,N-dimethylglycyl-N-(2-hyrdoxy-3-(((4-methoxyphenyl)sulphonyl)(2-methylpropyl)amino)-1-(phenylmethyl)propyl)-3-methyl-L-valinamide), KNI-272, CGP 53437, CGP 57813 and U-103017.</p>
    <p>In a preferred embodiment of the present invention, there is disclosed a method for improving the pharmacokinetics of an HIV protease inhibitor (or a pharmaceutically acceptable salt thereof) which is metabolized by cytochrome P450 monooxygenase comprising coadministering ritonavir or a pharmaceutically acceptable salt thereof. Such a combination of ritonavir or a pharmaceutically acceptable salt thereof and an HIV protease inhibitor or a pharmaceutically acceptable salt thereof which is metabolized by cytochrome P450 monooxygenase is useful for inhibiting HIV protease in humans and is also useful for inhibition, treatment or prophylaxis of an HIV infection or AIDS (acquired immune deficiency syndrome) in humans. When administered in combination, the two therapeutic agents can be formulated as separate compositions which are administered at the same time or different times, or the two therapeutic agents can be administered as a single composition.</p>
    <p>Preferred HIV protease inhibitors which are metabolized by cytochrome P450 monooxygenase include A-77003, A-80987, MK-639, saquinavir, VX-478 and AG1343.</p>
    <p>Ritonavir is (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof. Ritonavir can be synthesized by the procedures disclosed in PCT Patent Application No. WO94/14436, published Jul. 7, 1994, and the U.S. patent application Ser. No. 08/469,965, filed Jun. 6, 1995, both of which are incorporated herein by reference.</p>
    <p>VX-478 is ##STR1## or a pharmaceutically acceptable salt thereof. VX-478 can by synthesized by the procedures disclosed in PCT Patent Application No. WO94/05639, published Mar. 17, 1994, which is incorporated herein by reference.</p>
    <p>A-77003 is (2S,3R,4S,5S)-2,5-Di-(N-((N-methyl)-N-((2-pyridinyl)methyl)amino)carbonylvalinylamino)-3,4-dihydroxy-1,6-diphenyl hexane or a pharmaceutically acceptable salt thereof and is disclosed in U.S. Pat. No. 5,142,056, issued Aug. 25, 1992, which is incorporated herein by reference.</p>
    <p>A-80987 is (2S,3S,5S)-2-(N-(N-((2-Pyridinyl)methoxycarbonyl)valinyl)-amino)-5-(N-(3-pyridinyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane or a pharmaceutically acceptable salt thereof and is disclosed in U.S. Pat. No. 5,354,866, issued Oct. 11, 1994, which is incorporated herein by reference.</p>
    <p>MK-639 is N-(2(R)-hydroxy-1(S)-indanyl)-2(R)-phenylmethyl-4(S)-hydroxy-5-(1-(4-(3-pyridylmethyl)-2(S)-N'-(t-butylcarboxamido)-piperazinyl))-pentaneamide or a pharmaceutically acceptable salt thereof and is disclosed in European Patent Application No. EP541168, published May 12, 1993 and U.S. Pat. No. 5,413,999, issued May 9, 1995, both of which are incorporated herein by reference.</p>
    <p>Saquinavir is N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-L-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide or a pharmaceutically acceptable salt thereof and is disclosed in U.S. Pat. No. 5,196,438, issued Mar. 23, 1993, which is incorporated herein by reference.</p>
    <p>AG1343 is ##STR2## or a pharmaceutically acceptable salt thereof and is disclosed in PCT Patent Application No. WO95/09843, published Apr. 13, 1995 and U.S. Pat. No. 5,484,926, issued Jan. 16, 1996, both of which are incorporated herein by reference.</p>
    <p>DMP-323 is ##STR3## or a pharmaceutically acceptable salt thereof and is disclosed in PCT Patent Application No. WO93/07128, published Apr. 15, 1993, which is incorporated herein by reference.</p>
    <p>XM-450 is ##STR4## or a pharmaceutically acceptable salt thereof and is disclosed in PCT Patent Application No. WO93/07128, published Apr. 15, 1993, which is incorporated herein by reference.</p>
    <p>BILA 2011 is ##STR5## or a pharmaceutically acceptable salt thereof and is disclosed in European Patent Application No. EP560268, published Sep. 15, 1993, which is incorporated herein by reference.</p>
    <p>BILA 1096 BS is ##STR6## or a pharmaceutically acceptable salt thereof and is disclosed in European Patent Application No. EP560268, published Sep. 15, 1993, which is incorporated herein by reference.</p>
    <p>BILA 2185 BS is ##STR7## or a pharmaceutically acceptable salt thereof and is disclosed in European Patent Application No. EP560268, published Sep. 15, 1993, which is incorporated herein by reference.</p>
    <p>BMS 186,318 is ##STR8## or a pharmaceutically acceptable salt thereof and is disclosed in European Patent Application No. EP580402, published Jan. 26, 1994, which is incorporated herein by reference.</p>
    <p>LB71262 is ##STR9## and is disclosed in European Patent Application No. EP687675, published Dec. 20, 1995, which is incorporated herein by reference.</p>
    <p>SC-52151 is [1S-[1R*(R*),2S*]}-N<sup>1</sup> [3-[[[(1,1-dimethylethyl)-amino]carbonyl](2-methylpropyl)amino]-2-hydroxy-1-(phenylmethyl)propyl]-2-[(2-quinolinylcarbonyl)amino]-butanediamide or a pharmaceutically acceptable salt thereof and is disclosed in PCT Patent Application No. WO92/08701, published May 29, 1992 and PCT Patent Application No. WO93/23368, published Nov. 25, 1993, both of which are incorporated herein by reference.</p>
    <p>SC-629 (N,N-dimethylglycyl-N-(2-hyrdoxy-3-(((4-methoxyphenyl)sulphonyl)(2-methylpropyl)amino)-1-(phenylmethyl)propyl)-3-methyl-L-valinamide) is ##STR10## or a pharmaceutically acceptable salt thereof and is disclosed in PCT Patent Application No. WO095/06030, published Mar. 2, 1995, which is incorporated herein by reference.</p>
    <p>KNI-272 is ##STR11## or a pharmaceutically acceptable salt thereof and is disclosed in European Patent Application No. EP574135, published Dec. 15, 1993, which is incorporated herein by reference.</p>
    <p>CGP 53437 is ##STR12## and is disclosed in European Patent Application No. EP532466, published Mar. 17, 1993, which is incorporated herein by reference.</p>
    <p>CGP 57813 is ##STR13## and is disclosed in European Patent Application No. EP618222, published Oct. 5, 1994, which is incorporated herein by reference.</p>
    <p>U-103017 is ##STR14## and is disclosed in PCT Patent Application No. WO94/418188, published Aug. 18, 1994, which is incorporated herein by reference.</p>
    <p>The terms "S" and "R" configuration are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-30.</p>
    <p>The term "Val" as used herein refers to valine. Unless otherwise noted, when "Val" is used herein it refers to the L-isomer. In general, the amino acid abbreviations used herein follow the IUPAC-IUB Joint Commission on Biochemical Nomenclature for amino acids and peptides (Eur. J. Biochem. 1984, 158, 9-31).</p>
    <p>The ability of a compound to inhibit HIV protease can be demonstrated according to the methods disclosed in PCT Patent Application No. WO94/14436.</p>
    <p>The ability of an HIV protease inhibitor to inhibit an HIV infection can be demonstrated according to the methods disclosed in PCT Patent Application No. WO94/14436.</p>
    <heading>Inhibition of Cytochrome P450</heading> <p>The ability of ritonavir to inhibit cytochrome P450 monooxygenase activity was tested with terfenadine as the probe substrate (Yun, et al., Drug Metabolism &amp; Disposition, Vol. 21 403-407 (1993)). Ritonavir inhibited the terfenadine hydroxylase activity representing the most abundant form of cytochrome P450 (CYP3A4) present in human liver with an IC<sub>50</sub> of 0.25 M.</p>
    <heading>PHARMACOKINETIC IMPROVEMENT</heading> <p>The ability of ritonavir to improve the pharmacokinetics of a compound which is metabolized by cytochrome P450 monooxygenase can be demonstrated by the test method described below, wherein VX-478 is used as an example.</p>
    <p>Rats (male, Sprague-Dawley derived, 0.3-0.45 kg) were fasted overnight prior to dosing, but were permitted water ad libitum. For combination dosing, a single solution containing both ritonavir and VX-478 (5 mg/ml each) was prepared in a vehicle of 20% ethanol:30% propylene glycol and D5W with an appropriate number of molar equivalents of methane sulfonic acid to assist in solubilization. Separate solutions of VX-478 and ritonavir were also prepared and these solutions were used to evaluate the pharmacokinetics of VX-478 and ritonavir when administered as a single agent in rats. The solutions, administered orally by gavage to a group of rats at a dose volume of 2 ml/kg, provided a 10 mg/kg dose of each compound. Blood samples were obtained from a tail vein of each rat 0.25, 0.5, 1, 1.5, 2, 3, 4, 6 and 8 hours after dosing. The plasma was separated from the red cells by centrifugation and frozen (-30 C.) until analysis. Concentrations of both ritonavir and VX-478 were determined simultaneously by reverse phase HPLC with low wavelength UV detection following liquid-liquid extraction of the plasma samples. The peak plasma concentration (C<sub>max</sub>) and time to peak plasma concentration (T<sub>max</sub>) for each rat were obtained directly from the plasma concentration data. The area under the curve was calculated by the trapezoidal method over the time course of the study. The plasma elimination half life was obtained from NONLIN84 or from a log-linear regression of the terminal plasma concentrations as a function of time after dosing. Each combination was evaluated in a group containing at least three rats; the values reported are averages for each group of animals. The data obtained from the combination was compared to data obtained from a separate group of rats which received a single, separate dose of the compound under evaluation.</p>
    <p>Below in Table 1 are shown the results from the pharmacokinetic experiments with VX-478 and other HIV protease inhibitors in rats. The maximum plasma levels (C<sub>max</sub>), time to maximum plasma level (T<sub>max</sub>) and area under the plasma concentration curve (AUC) for an 8-hour sampling interval following dosing of the HIV protease inhibitor alone vs. dosing in combination with ritonavir are provided.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 1______________________________________         Cmax       Tmax   AUC(0-8 h)  Compound (mcg/ml) (hr) (mcg  hr/ml)______________________________________VX-478         1.61        0.42  1.69  VX-478 (+ritonavir) 2.88 1.5 13.50  A-77003 0.07  0.25  0.025  A-77003 (+ritonavir) 0.96  0.67 1.39  A-80987 2.42  0.25 1.45  A-80987 (+ritonavir) 4.47 1.7 25.74  Saquinavir 0.08  0.18  0.029  Saquinavir (+ritonavir) 1.48 3.0 8.52  MK-639 1.03 0.5 0.81  MK-639 (+ritonavir) 1.40 3.0 6.51  AG1343 0.40  0.75 1.14  AG1343 (+ritonavir) 1.81 4.0 11.92______________________________________ compound administered as a single agent</pre>
    
    <p>The ability of ritonavir to improve the pharmacokinetics of clarithromycin in humans was demonstrated according to the method described below.</p>
    <p>Clarithromycin (500 mg/BIAXIN tablet every 12 hours) and a combination of ritonavir (200 mg of liquid formulation every 8 hours) and clarithromycin (500 mg every 12 hours) were administered to groups of 4 healthy human volunteers. Blood samples were collected on day four of dosing for HPLC determination of plasma concentrations of clarithromycin.</p>
    <p>Below in Table 2 are shown the results from the pharmacokinetic experiments with clarithromycin in humans. The mean maximum plasma levels (C<sub>max</sub>) and area under the plasma concentration curve (AUC) calculated using noncompartmental methods for the 0-24 hour time interval on day four of dosing of clarithromycin alone vs. dosing in combination with ritonavir are provided.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 2______________________________________             Cmax     AUC(0-24 h)  Compound (mcg/ml) (mcg  hr/ml)______________________________________clarithromycin             3.93     49.04  clarithromycin (+ritonavir) 5.13 86.88______________________________________ compound administered as a single agent</pre>
    
    <p>The therapeutic agents of the present invention can be used in the form of salts derived from inorganic or organic acids. These salts include but are not limited to the following: acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, cyclopentanepropionate, dodecylsulfate, ethanesulfonate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxy-ethanesulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as loweralkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others. Water or oil-soluble or dispersible products are thereby obtained.</p>
    <p>Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. Other salts include salts with alkali metals or alkaline earth metals, such as sodium, potassium, calcium or magnesium or with organic bases.</p>
    <p>The administration of ritonavir and a compound which is metabolized by cytochrome P450 monooxygenase is useful for improving in humans the pharmacokinetics of the compound which is metabolized by cytochrome P450 monooxygenase.</p>
    <p>In particular, the administration of ritonavir and an HlV protease inhibitor which is metabolized by cytochrome P450 monooxygenase is useful for improving in humans the pharmacokinetics of the HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase.</p>
    <p>The combination of ritonavir and an HIV protease inhibitor which is metabolized by cytochrome P450 monooxygenase is also useful for inhibiting a retroviral protease, in particular HIV protease, in vitro or in vivo (especially in mammals and in particular in humans). This combination of therapeutic agents is also useful for the inhibition of retroviruses in vivo, especially human immunodeficiency virus (HIV). This combination of therapeutic agents is also useful for the treatment or prophylaxis of diseases caused by retroviruses, especially acquired immune deficiency syndrome or an HIV infection, in a human or other mammal.</p>
    <p>The total daily dose of ritonavir to be administered to a human or other mammal host in single or divided doses may be in amounts, for example, from 0.001 to 300 mg/kg body weight daily and more usually 0.1 to 50 mg/kg and even more usually 0.1 to 25 mg/kg. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.</p>
    <p>The total daily dose of the drug which is metabolized by cytochrome P450 monooxygenase to be administered to a human or other mammal is well known and can be readily determined by one of ordinary skill in the art. Dosage unit compositions may contain such amounts of submultiples thereof to make up the daily dose.</p>
    <p>The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form of each drug, individually or in combination, will vary depending upon the host treated and the particular mode of administration.</p>
    <p>It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the particular disease undergoing therapy.</p>
    <p>The combination of therapeutic agents of the present invention (as individual compositions or as a single composition) may be administered orally, parenterally, sublingually, by inhalation spray, rectally, or topically in dosage unit formulations containing conventional nontoxic pharmaceutically acceptable carriers, adjuvants, and vehicles as desired. Topical administration may also involve the use of transdermal administration such as transdermal patches or iontophoresis devices. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection, or infusion techniques.</p>
    <p>Injectable preparations, for example, sterile injectable aqueous or oleagenous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-propanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.</p>
    <p>Suppositories for rectal administration of the drug can be prepared by mixing the drug with a suitable nonirritating excipient such as cocoa butter and polyethylene glycols which are solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum and release the drug.</p>
    <p>Solid dosage forms for oral administration may include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound may be admixed with at least one inert diluent such as sucrose lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., lubricating agents such as magnesium stearate. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.</p>
    <p>Liquid dosage forms for oral administration may include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs containing inert diluents commonly used in the art, such as water. Such compositions may also comprise adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.</p>
    <p>The combination of therapeutic agents of the present invention (as individual compositions or as a single composition) can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically aceptable and metabolizable lipid capabale of forming liposomes can be used. The present compositions in liposome form can contain, in addition to the compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and phosphatidyl cholines (lecithins), both natureal and synthetic.</p>
    <p>Methods to form liposomes are known in the art. See, for example, Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.</p>
    <p>Preferred dosage forms for ritonavir include (a) a liquid dosage form for oral administration as disclosed in U.S. Ser. No. 08/283, 239, filed Jul. 29, 1994 (now U.S. Pat. No. 5,484,801, issued Jan. 16, 1996), which is incorporated herein by reference, (b) an encapsulated solid or semi-solid dosage form as disclosed in PCT Patent Application No. WO95/07696, published Mar. 23, 1995 and U.S. Ser. No. 08/402,690, filed March 13, 1995, both of which are incorporated herein by reference and (c) an encapsulated solid dosage form as disclosed in PCT Patent Application No. WO95/09614, published Apr. 13, 1995, which is incorporated herein by reference.</p>
    <p>The foregoing is merely illustrative of the invention and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are intended to be within the scope and nature of the invention which are defined in the appended claims.</p>
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5547823">US5547823</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Nov 9, 1995</td><td class="patent-data-table-td patent-date-value">Aug 20, 1996</td><td class="patent-data-table-td ">Ishihara Sangyo Kaisha, Ltd.</td><td class="patent-data-table-td ">Photocatalyst composite and process for producing the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5552558">US5552558</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 27, 1995</td><td class="patent-data-table-td patent-date-value">Sep 3, 1996</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Retroviral protease inhibiting compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5674882">US5674882</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 29, 1995</td><td class="patent-data-table-td patent-date-value">Oct 7, 1997</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Retroviral protease inhibiting compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5886036">US5886036</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 20, 1997</td><td class="patent-data-table-td patent-date-value">Mar 23, 1999</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Treating hiv infections</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0691345A2?cl=en">EP0691345A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 5, 1995</td><td class="patent-data-table-td patent-date-value">Jan 10, 1996</td><td class="patent-data-table-td ">Bristol-Myers Squibb Company</td><td class="patent-data-table-td ">HIV protease inhibitor combinations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1995011992A1?cl=en">WO1995011992A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 26, 1994</td><td class="patent-data-table-td patent-date-value">May 4, 1995</td><td class="patent-data-table-td ">Univ California</td><td class="patent-data-table-td ">Antiviral compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1995033464A2?cl=en">WO1995033464A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 2, 1995</td><td class="patent-data-table-td patent-date-value">Dec 14, 1995</td><td class="patent-data-table-td ">Martin L Bryant</td><td class="patent-data-table-td ">Retroviral protease inhibitor combinations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO1996004913A1?cl=en">WO1996004913A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 7, 1995</td><td class="patent-data-table-td patent-date-value">Feb 22, 1996</td><td class="patent-data-table-td ">Merck &amp; Co Inc</td><td class="patent-data-table-td ">Hiv protease inhibitor combination</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">D, Kempf, et al., 3rd Conf Retro and Opportun Infect (US) Jan. 28 Feb. 1, 1996 p. 79.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">D, Kempf, et al., 3rd Conf Retro and Opportun Infect (US) Jan. 28-Feb. 1, 1996 p. 79.</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">J. Craig, et al., Int. Conf. AIDS 9(1993) PO A25 0602 RO 31 8959, An Inhibitor of HIV Proteinase, Acts Beneficially with Other Antiviral Agents in 2 and 3 Way Combinations In Vitro.</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">J. Craig, et al., Int. Conf. AIDS 9(1993) PO-A25-0602 RO 31-8959, An Inhibitor of HIV Proteinase, Acts Beneficially with Other Antiviral Agents in 2- and 3-Way Combinations In Vitro.</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">J. James, AIDS Treatment News, No. 231 Sep. 29, 1995.</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">S. Vella, Rationale and Experience with Reverse Transcriptase Inhibitors and Protease Inhibitors, Journ of Acquired Immune Def. Syndrome &amp; Humane Retro. 10(Suppl. 1) S58 S61 1995.</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">S. Vella, Rationale and Experience with Reverse Transcriptase Inhibitors and Protease Inhibitors, Journ of Acquired Immune Def. Syndrome &amp; Humane Retro. 10(Suppl. 1) S58-S61 1995.</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6284767">US6284767</a></td><td class="patent-data-table-td patent-date-value">Dec 8, 1998</td><td class="patent-data-table-td patent-date-value">Sep 4, 2001</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Retroviral protease inhibiting compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6472529">US6472529</a></td><td class="patent-data-table-td patent-date-value">Apr 18, 2001</td><td class="patent-data-table-td patent-date-value">Oct 29, 2002</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Viricides</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6703403">US6703403</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 20, 2001</td><td class="patent-data-table-td patent-date-value">Mar 9, 2004</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Method for improving pharmacokinetics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7205413">US7205413</a></td><td class="patent-data-table-td patent-date-value">May 1, 2003</td><td class="patent-data-table-td patent-date-value">Apr 17, 2007</td><td class="patent-data-table-td ">Transform Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Comprises formamide solvent; for treatment of HIV/inhibiting proteases; crystal structure; kits</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7208600">US7208600</a></td><td class="patent-data-table-td patent-date-value">Oct 12, 2004</td><td class="patent-data-table-td patent-date-value">Apr 24, 2007</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Inhibitors of serine proteases, particularly HCV NS3-NS4A proteases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7279582">US7279582</a></td><td class="patent-data-table-td patent-date-value">Oct 25, 2002</td><td class="patent-data-table-td patent-date-value">Oct 9, 2007</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">For example (2S, 3S, 5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-(2S-(1-tetrahydro-pyrimid-2-onyl)-3-methyl butanoyl)amino-1,6-diphenylhexane; HIV therapy</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7320961">US7320961</a></td><td class="patent-data-table-td patent-date-value">Mar 18, 2004</td><td class="patent-data-table-td patent-date-value">Jan 22, 2008</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">UDP-glucuronosyltransferases (UGTs), UGT1A1 being a bilirubin-specific isozyme; inducing UGT1A1 isoform expression for treating unconjugated hyperbilirubinemia by administering ritonavir; side effect reduction of AIDS drugs such as indinavir, atazanavir, amphotericin B/cholesteryl sulfate complex</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7364752">US7364752</a></td><td class="patent-data-table-td patent-date-value">Nov 10, 2000</td><td class="patent-data-table-td patent-date-value">Apr 29, 2008</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Solid dispersion pharamaceutical formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7378422">US7378422</a></td><td class="patent-data-table-td patent-date-value">Sep 7, 2004</td><td class="patent-data-table-td patent-date-value">May 27, 2008</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Inhibitors of serine proteases, particularly HCV NS3-NS4A protease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7494660">US7494660</a></td><td class="patent-data-table-td patent-date-value">Oct 27, 2004</td><td class="patent-data-table-td patent-date-value">Feb 24, 2009</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">HCV NS3-NS4A protease resistance mutants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7547678">US7547678</a></td><td class="patent-data-table-td patent-date-value">Jan 15, 2008</td><td class="patent-data-table-td patent-date-value">Jun 16, 2009</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Using expression vector comprising UDP-glucuronosyltransferase (UGTIAI) as gene transfer tool in treatment of hyperbilirubinemia</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7666834">US7666834</a></td><td class="patent-data-table-td patent-date-value">Jul 28, 2006</td><td class="patent-data-table-td patent-date-value">Feb 23, 2010</td><td class="patent-data-table-td ">Tibotec Pharmaceuticals Ltd.</td><td class="patent-data-table-td ">(2-Pyrazol-1-yl-5-trifluoromethylphenyl)carbamic acid 4-cyclopropanesulfonylamino-carbonyl-13-methyl-2,14-dioxo-3,13-diazatricyclo-[13.3.0.04,6]octadec-7-en-17-yl ester; viricides; potency, decreased cytotoxicity, improved pharmacokinetics, improved resistance profile; liver disorders; ritonavir</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7705138">US7705138</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2006</td><td class="patent-data-table-td patent-date-value">Apr 27, 2010</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Hepatitis C virus variants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7745444">US7745444</a></td><td class="patent-data-table-td patent-date-value">Apr 10, 2008</td><td class="patent-data-table-td patent-date-value">Jun 29, 2010</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Inhibitors of serine proteases, particularly HCV NS3-NS4A protease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7820671">US7820671</a></td><td class="patent-data-table-td patent-date-value">Aug 31, 2001</td><td class="patent-data-table-td patent-date-value">Oct 26, 2010</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Hepatitis C antiviral agents including telaprevir (VX 950); higher tolerance, reduced side effects; azaheterocyclic amido ketone derivatives</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7820681">US7820681</a></td><td class="patent-data-table-td patent-date-value">Feb 17, 2009</td><td class="patent-data-table-td patent-date-value">Oct 26, 2010</td><td class="patent-data-table-td ">Mutual Pharmaceutical Company, Inc.</td><td class="patent-data-table-td ">Methods for concomitant administration of colchicine and a second active agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7884199">US7884199</a></td><td class="patent-data-table-td patent-date-value">Nov 17, 2008</td><td class="patent-data-table-td patent-date-value">Feb 8, 2011</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">HCV NS3-NS4 protease resistance mutants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7906519">US7906519</a></td><td class="patent-data-table-td patent-date-value">Aug 18, 2010</td><td class="patent-data-table-td patent-date-value">Mar 15, 2011</td><td class="patent-data-table-td ">Ar Holding Company, Inc.</td><td class="patent-data-table-td ">Methods for concomitant administration of colchicine and a second active agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7915269">US7915269</a></td><td class="patent-data-table-td patent-date-value">Aug 18, 2010</td><td class="patent-data-table-td patent-date-value">Mar 29, 2011</td><td class="patent-data-table-td ">Ar Holding Company, Inc.</td><td class="patent-data-table-td ">treating gout with ritonavir; side effect reduction of colchicine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7935731">US7935731</a></td><td class="patent-data-table-td patent-date-value">May 25, 2010</td><td class="patent-data-table-td patent-date-value">May 3, 2011</td><td class="patent-data-table-td ">Mutual Pharmaceutical Company, Inc.</td><td class="patent-data-table-td ">Methods for concomitant administration of colchicine and macrolide antibiotics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7964624">US7964624</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2007</td><td class="patent-data-table-td patent-date-value">Jun 21, 2011</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Inhibitors of serine proteases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7964648">US7964648</a></td><td class="patent-data-table-td patent-date-value">Jan 15, 2010</td><td class="patent-data-table-td patent-date-value">Jun 21, 2011</td><td class="patent-data-table-td ">Mutual Pharmaceutical Company, Inc.</td><td class="patent-data-table-td ">Methods for concomitant administration of colchicine and a second active agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7968707">US7968707</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2007</td><td class="patent-data-table-td patent-date-value">Jun 28, 2011</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Reacting an amino, hydroxy substituted amide with a heterocyclic substituted carboxylic acid to produce (2S,3S,5S)-2-(2,6-Dimethylphenoxyacetyl) amino-3-hydroxy-5-[2S-1-imidazolidin-2-onyl)-3-methyl-butanoyl] amino-1,6-diphenylhexane; inhibitors of HIV infection</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7985762">US7985762</a></td><td class="patent-data-table-td patent-date-value">Aug 28, 2006</td><td class="patent-data-table-td patent-date-value">Jul 26, 2011</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Inhibitors of serine proteases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7989471">US7989471</a></td><td class="patent-data-table-td patent-date-value">Jul 28, 2006</td><td class="patent-data-table-td patent-date-value">Aug 2, 2011</td><td class="patent-data-table-td ">Tibotec Pharmaceuticals Ltd.</td><td class="patent-data-table-td ">Macrocyclic inhibitors of hepatitis C virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8008251">US8008251</a></td><td class="patent-data-table-td patent-date-value">Jul 28, 2006</td><td class="patent-data-table-td patent-date-value">Aug 30, 2011</td><td class="patent-data-table-td ">Tibotec Pharmaceuticals Ltd.</td><td class="patent-data-table-td ">Macrocyclic inhibitors of hepatitis C virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8012939">US8012939</a></td><td class="patent-data-table-td patent-date-value">Jul 28, 2006</td><td class="patent-data-table-td patent-date-value">Sep 6, 2011</td><td class="patent-data-table-td ">Tibotec Pharmaceuticals Ltd. Co</td><td class="patent-data-table-td ">Macrocyclic inhibitors of hepatitis C virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8025899">US8025899</a></td><td class="patent-data-table-td patent-date-value">Aug 25, 2004</td><td class="patent-data-table-td patent-date-value">Sep 27, 2011</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Solid pharmaceutical dosage form</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8030307">US8030307</a></td><td class="patent-data-table-td patent-date-value">Nov 26, 2008</td><td class="patent-data-table-td patent-date-value">Oct 4, 2011</td><td class="patent-data-table-td ">Enanta Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8039475">US8039475</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2007</td><td class="patent-data-table-td patent-date-value">Oct 18, 2011</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Co-crystals and pharmaceutical compositions comprising the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8039623">US8039623</a></td><td class="patent-data-table-td patent-date-value">Mar 9, 2007</td><td class="patent-data-table-td patent-date-value">Oct 18, 2011</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Peptidomimetics compound; viricides; interference in life cycle og hepatitis c virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8073632">US8073632</a></td><td class="patent-data-table-td patent-date-value">Dec 30, 2008</td><td class="patent-data-table-td patent-date-value">Dec 6, 2011</td><td class="patent-data-table-td ">The Invention Science Fund I, Llc</td><td class="patent-data-table-td ">Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8073633">US8073633</a></td><td class="patent-data-table-td patent-date-value">Dec 30, 2008</td><td class="patent-data-table-td patent-date-value">Dec 6, 2011</td><td class="patent-data-table-td ">The Invention Science Fund I, Llc</td><td class="patent-data-table-td ">Computational methods and systems for suggesting modulators of CYP450 as treatment options</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8093296">US8093296</a></td><td class="patent-data-table-td patent-date-value">Apr 20, 2011</td><td class="patent-data-table-td patent-date-value">Jan 10, 2012</td><td class="patent-data-table-td ">Mutual Pharmaceutical Company, Inc.</td><td class="patent-data-table-td ">Methods for concomitant administration of colchicine and macrolide antibiotics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8093297">US8093297</a></td><td class="patent-data-table-td patent-date-value">Apr 22, 2011</td><td class="patent-data-table-td patent-date-value">Jan 10, 2012</td><td class="patent-data-table-td ">Mutual Pharmaceutical Company, Inc.</td><td class="patent-data-table-td ">Methods for concomitant administration of colchicine and a second active agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8093298">US8093298</a></td><td class="patent-data-table-td patent-date-value">May 18, 2011</td><td class="patent-data-table-td patent-date-value">Jan 10, 2012</td><td class="patent-data-table-td ">Mutual Pharmaceutical Company, Inc.</td><td class="patent-data-table-td ">Methods for concomitant administration of colchicine and macrolide antibiotics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8097655">US8097655</a></td><td class="patent-data-table-td patent-date-value">May 17, 2011</td><td class="patent-data-table-td patent-date-value">Jan 17, 2012</td><td class="patent-data-table-td ">Mutual Pharmaceutical Company, Inc.</td><td class="patent-data-table-td ">Methods for concomitant administration of colchicine and macrolide antibiotics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8183277">US8183277</a></td><td class="patent-data-table-td patent-date-value">Jul 28, 2006</td><td class="patent-data-table-td patent-date-value">May 22, 2012</td><td class="patent-data-table-td ">Tibotec Pharmaceuticals Ltd.</td><td class="patent-data-table-td ">Inhibitors of HCV replication of formula (I)** Image-1whereinW is a heterocycle of formula** Image-2and the remaining variables are as defined in the specification.</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8217048">US8217048</a></td><td class="patent-data-table-td patent-date-value">Jun 28, 2010</td><td class="patent-data-table-td patent-date-value">Jul 10, 2012</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Inhibitors of serine proteases, particularly HCV NS3-NS4A protease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8227407">US8227407</a></td><td class="patent-data-table-td patent-date-value">Jan 16, 2008</td><td class="patent-data-table-td patent-date-value">Jul 24, 2012</td><td class="patent-data-table-td ">Medivir Ab</td><td class="patent-data-table-td ">Macrocyclic inhibitors of hepatitis C virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8247532">US8247532</a></td><td class="patent-data-table-td patent-date-value">Nov 24, 2010</td><td class="patent-data-table-td patent-date-value">Aug 21, 2012</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Deuterated hepatitis C protease inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8252923">US8252923</a></td><td class="patent-data-table-td patent-date-value">Sep 8, 2008</td><td class="patent-data-table-td patent-date-value">Aug 28, 2012</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Peptidomimetic protease inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8263549">US8263549</a></td><td class="patent-data-table-td patent-date-value">Nov 26, 2008</td><td class="patent-data-table-td patent-date-value">Sep 11, 2012</td><td class="patent-data-table-td ">Enanta Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">C5-substituted, proline-derived, macrocyclic hepatitis C serine protease inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8268349">US8268349</a></td><td class="patent-data-table-td patent-date-value">Apr 18, 2012</td><td class="patent-data-table-td patent-date-value">Sep 18, 2012</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Solid pharmaceutical dosage form</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8268776">US8268776</a></td><td class="patent-data-table-td patent-date-value">Jan 18, 2008</td><td class="patent-data-table-td patent-date-value">Sep 18, 2012</td><td class="patent-data-table-td ">Enanta Pharmaceuticals, Inc.</td><td class="patent-data-table-td ">mixture of cytochrome P450 monooxygenase inhibitor and protease inhibitor for anti-hepatitis C viral treatment; including other active drugs as interferon, ribavarin, and adamantine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8309613">US8309613</a></td><td class="patent-data-table-td patent-date-value">Sep 13, 2010</td><td class="patent-data-table-td patent-date-value">Nov 13, 2012</td><td class="patent-data-table-td ">Abbvie Inc.</td><td class="patent-data-table-td ">Solid pharmaceutical dosage form</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8314141">US8314141</a></td><td class="patent-data-table-td patent-date-value">Feb 14, 2008</td><td class="patent-data-table-td patent-date-value">Nov 20, 2012</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8315815">US8315815</a></td><td class="patent-data-table-td patent-date-value">Oct 28, 2011</td><td class="patent-data-table-td patent-date-value">Nov 20, 2012</td><td class="patent-data-table-td ">The Invention Science Fund I, Llc</td><td class="patent-data-table-td ">Computational methods and systems for suggesting modulators of CYP450 as treatment options</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8321151">US8321151</a></td><td class="patent-data-table-td patent-date-value">Oct 28, 2011</td><td class="patent-data-table-td patent-date-value">Nov 27, 2012</td><td class="patent-data-table-td ">The Invention Science Fund I, Llc</td><td class="patent-data-table-td ">Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8333990">US8333990</a></td><td class="patent-data-table-td patent-date-value">Sep 13, 2010</td><td class="patent-data-table-td patent-date-value">Dec 18, 2012</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Solid pharmaceutical dosage form</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8350048">US8350048</a></td><td class="patent-data-table-td patent-date-value">Dec 5, 2008</td><td class="patent-data-table-td patent-date-value">Jan 8, 2013</td><td class="patent-data-table-td ">Janssen R&amp;D Ireland</td><td class="patent-data-table-td ">Amide compounds as boosters of antivirals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8372846">US8372846</a></td><td class="patent-data-table-td patent-date-value">Oct 10, 2011</td><td class="patent-data-table-td patent-date-value">Feb 12, 2013</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Co-crystals and pharmaceutical compositions comprising the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8372873">US8372873</a></td><td class="patent-data-table-td patent-date-value">Mar 29, 2011</td><td class="patent-data-table-td patent-date-value">Feb 12, 2013</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Inhibitors of serine proteases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8377952">US8377952</a></td><td class="patent-data-table-td patent-date-value">Feb 23, 2005</td><td class="patent-data-table-td patent-date-value">Feb 19, 2013</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Solid pharmaceutical dosage formulation</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8383655">US8383655</a></td><td class="patent-data-table-td patent-date-value">May 9, 2011</td><td class="patent-data-table-td patent-date-value">Feb 26, 2013</td><td class="patent-data-table-td ">Gilead Sciences, Inc.</td><td class="patent-data-table-td ">Modulators of pharmacokinetic properties of therapeutics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8399015">US8399015</a></td><td class="patent-data-table-td patent-date-value">Sep 22, 2011</td><td class="patent-data-table-td patent-date-value">Mar 19, 2013</td><td class="patent-data-table-td ">Abbvie Inc.</td><td class="patent-data-table-td ">Solid pharmaceutical dosage form</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8431588">US8431588</a></td><td class="patent-data-table-td patent-date-value">Jul 1, 2009</td><td class="patent-data-table-td patent-date-value">Apr 30, 2013</td><td class="patent-data-table-td ">Janssen Products, Lp</td><td class="patent-data-table-td ">Cyclopropyl polymerase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8440706">US8440706</a></td><td class="patent-data-table-td patent-date-value">Feb 28, 2011</td><td class="patent-data-table-td patent-date-value">May 14, 2013</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Inhibitors of serine proteases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8440721">US8440721</a></td><td class="patent-data-table-td patent-date-value">Jul 18, 2011</td><td class="patent-data-table-td patent-date-value">May 14, 2013</td><td class="patent-data-table-td ">Takeda Pharmaceuticals U.S.A., Inc.</td><td class="patent-data-table-td ">Methods for concomitant administration of colchicine and a second active agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8440722">US8440722</a></td><td class="patent-data-table-td patent-date-value">Apr 24, 2012</td><td class="patent-data-table-td patent-date-value">May 14, 2013</td><td class="patent-data-table-td ">Takeda Pharamceuticals U.S.A., Inc.</td><td class="patent-data-table-td ">Methods for concomitant administration of colchicine and a second active agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8445541">US8445541</a></td><td class="patent-data-table-td patent-date-value">Apr 24, 2012</td><td class="patent-data-table-td patent-date-value">May 21, 2013</td><td class="patent-data-table-td ">Takeda Pharmaceuticals U.S.A., Inc.</td><td class="patent-data-table-td ">Methods for concomitant administration of colchicine and a second active agent</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8470347">US8470347</a></td><td class="patent-data-table-td patent-date-value">May 29, 2001</td><td class="patent-data-table-td patent-date-value">Jun 25, 2013</td><td class="patent-data-table-td ">AbbVie Deutschland GmbH and Co KG</td><td class="patent-data-table-td ">Mixture of active materials, lipid and binder</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8486942">US8486942</a></td><td class="patent-data-table-td patent-date-value">Nov 21, 2011</td><td class="patent-data-table-td patent-date-value">Jul 16, 2013</td><td class="patent-data-table-td ">Gilead Sciencs, Inc.</td><td class="patent-data-table-td ">Modulators of pharmacokinetic properties of therapeutics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8492546">US8492546</a></td><td class="patent-data-table-td patent-date-value">Aug 29, 2008</td><td class="patent-data-table-td patent-date-value">Jul 23, 2013</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Co-crystals and pharmaceutical compositions comprising the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8501450">US8501450</a></td><td class="patent-data-table-td patent-date-value">Mar 5, 2010</td><td class="patent-data-table-td patent-date-value">Aug 6, 2013</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Hepatitis C virus variants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8529882">US8529882</a></td><td class="patent-data-table-td patent-date-value">Jul 3, 2012</td><td class="patent-data-table-td patent-date-value">Sep 10, 2013</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Peptidomimetic protease inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8637663">US8637663</a></td><td class="patent-data-table-td patent-date-value">Nov 16, 2007</td><td class="patent-data-table-td patent-date-value">Jan 28, 2014</td><td class="patent-data-table-td ">Janssen R&amp;D Ireland</td><td class="patent-data-table-td ">Macrocyclic inhibitors of hepatitis C virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8664391">US8664391</a></td><td class="patent-data-table-td patent-date-value">Oct 7, 2009</td><td class="patent-data-table-td patent-date-value">Mar 4, 2014</td><td class="patent-data-table-td ">Janssen R&amp;D Ireland Ltd</td><td class="patent-data-table-td ">Amide compounds as boosters of antivirals</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8691878">US8691878</a></td><td class="patent-data-table-td patent-date-value">Nov 12, 2012</td><td class="patent-data-table-td patent-date-value">Apr 8, 2014</td><td class="patent-data-table-td ">Abbvie Inc.</td><td class="patent-data-table-td ">Solid pharmaceutical dosage form</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8754105">US8754105</a></td><td class="patent-data-table-td patent-date-value">May 17, 2011</td><td class="patent-data-table-td patent-date-value">Jun 17, 2014</td><td class="patent-data-table-td ">Medivir Ab</td><td class="patent-data-table-td ">Macrocyclic inhibitors of hepatitis C virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8754106">US8754106</a></td><td class="patent-data-table-td patent-date-value">Mar 15, 2013</td><td class="patent-data-table-td patent-date-value">Jun 17, 2014</td><td class="patent-data-table-td ">Janssen R&amp;D Ireland</td><td class="patent-data-table-td ">Macrocyclic inhibitors of hepatitis C virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8754116">US8754116</a></td><td class="patent-data-table-td patent-date-value">Apr 20, 2012</td><td class="patent-data-table-td patent-date-value">Jun 17, 2014</td><td class="patent-data-table-td ">Janssen R&amp;D Ireland</td><td class="patent-data-table-td ">Macrocyclic inhibitors of hepatitis C virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8759353">US8759353</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2008</td><td class="patent-data-table-td patent-date-value">Jun 24, 2014</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Co-crystals and pharmaceutical compositions comprising the same</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/USRE42889">USRE42889</a></td><td class="patent-data-table-td patent-date-value">Apr 23, 2007</td><td class="patent-data-table-td patent-date-value">Nov 1, 2011</td><td class="patent-data-table-td ">G.D. Searle Llc</td><td class="patent-data-table-td ">- and - amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/USRE43596">USRE43596</a></td><td class="patent-data-table-td patent-date-value">Apr 23, 2007</td><td class="patent-data-table-td patent-date-value">Aug 21, 2012</td><td class="patent-data-table-td ">G.D. Searle Llc</td><td class="patent-data-table-td ">- and -amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/USRE43802">USRE43802</a></td><td class="patent-data-table-td patent-date-value">Sep 21, 2011</td><td class="patent-data-table-td patent-date-value">Nov 13, 2012</td><td class="patent-data-table-td ">G.D. Searle Llc</td><td class="patent-data-table-td ">- and -amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1944042A1?cl=en">EP1944042A1</a></td><td class="patent-data-table-td patent-date-value">Oct 27, 2004</td><td class="patent-data-table-td patent-date-value">Jul 16, 2008</td><td class="patent-data-table-td ">Vertex Pharmceuticals Incorporated</td><td class="patent-data-table-td ">Combinations for HCV treatment</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2141172A1?cl=en">EP2141172A1</a></td><td class="patent-data-table-td patent-date-value">Jul 1, 2009</td><td class="patent-data-table-td patent-date-value">Jan 6, 2010</td><td class="patent-data-table-td ">Ortho Biotech Products L.P.</td><td class="patent-data-table-td ">Cyclopropyl polymerase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2256113A1?cl=en">EP2256113A1</a></td><td class="patent-data-table-td patent-date-value">Aug 1, 2006</td><td class="patent-data-table-td patent-date-value">Dec 1, 2010</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Inhibitors of serine proteases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2279728A1?cl=en">EP2279728A1</a></td><td class="patent-data-table-td patent-date-value">Aug 2, 2010</td><td class="patent-data-table-td patent-date-value">Feb 2, 2011</td><td class="patent-data-table-td ">Ranbaxy Laboratories Limited</td><td class="patent-data-table-td ">Solid dosage forms of HIV protease inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2308490A1?cl=en">EP2308490A1</a></td><td class="patent-data-table-td patent-date-value">Dec 29, 2006</td><td class="patent-data-table-td patent-date-value">Apr 13, 2011</td><td class="patent-data-table-td ">Gilead Sciences, Inc.</td><td class="patent-data-table-td ">Methods for improving the pharmacokinetics of hiv integrase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2311851A2?cl=en">EP2311851A2</a></td><td class="patent-data-table-td patent-date-value">Feb 4, 2005</td><td class="patent-data-table-td patent-date-value">Apr 20, 2011</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Inhibitors of serine proteases, particularly HCV NS3-NS4A protease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2322516A1?cl=en">EP2322516A1</a></td><td class="patent-data-table-td patent-date-value">Jul 28, 2006</td><td class="patent-data-table-td patent-date-value">May 18, 2011</td><td class="patent-data-table-td ">Tibotec Pharmaceuticals Ltd.</td><td class="patent-data-table-td ">Intermediates for the preparation of Macrocyclic inhibitors of hepatitis c virus</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2361925A1?cl=en">EP2361925A1</a></td><td class="patent-data-table-td patent-date-value">Oct 8, 2004</td><td class="patent-data-table-td patent-date-value">Aug 31, 2011</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Inhibitors of serine proteases, particularly HCV NS3-NS4A protease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2374464A2?cl=en">EP2374464A2</a></td><td class="patent-data-table-td patent-date-value">Sep 30, 2005</td><td class="patent-data-table-td patent-date-value">Oct 12, 2011</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">HCV N3S-NS4A protease inhibition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2392588A2?cl=en">EP2392588A2</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2006</td><td class="patent-data-table-td patent-date-value">Dec 7, 2011</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Hepatitis C virus variants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2392589A2?cl=en">EP2392589A2</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2006</td><td class="patent-data-table-td patent-date-value">Dec 7, 2011</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Hepatitis C virus variants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2392590A2?cl=en">EP2392590A2</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2006</td><td class="patent-data-table-td patent-date-value">Dec 7, 2011</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Hepatitis C virus variants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2444070A1?cl=en">EP2444070A1</a></td><td class="patent-data-table-td patent-date-value">Feb 27, 2009</td><td class="patent-data-table-td patent-date-value">Apr 25, 2012</td><td class="patent-data-table-td ">Abbott Laboratories</td><td class="patent-data-table-td ">Tablets</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2500021A1?cl=en">EP2500021A1</a></td><td class="patent-data-table-td patent-date-value">Oct 31, 2005</td><td class="patent-data-table-td patent-date-value">Sep 19, 2012</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Inc.</td><td class="patent-data-table-td ">Therapeutic uses of VX-950</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2505193A1?cl=en">EP2505193A1</a></td><td class="patent-data-table-td patent-date-value">Dec 24, 2008</td><td class="patent-data-table-td patent-date-value">Oct 3, 2012</td><td class="patent-data-table-td ">Cipla Ltd.</td><td class="patent-data-table-td ">Anti - retroviral combination</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2518079A2?cl=en">EP2518079A2</a></td><td class="patent-data-table-td patent-date-value">Apr 9, 2007</td><td class="patent-data-table-td patent-date-value">Oct 31, 2012</td><td class="patent-data-table-td ">Novartis AG</td><td class="patent-data-table-td ">HCV/HIV inhibitors and their uses</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP2573083A1?cl=en">EP2573083A1</a></td><td class="patent-data-table-td patent-date-value">Sep 7, 2004</td><td class="patent-data-table-td patent-date-value">Mar 27, 2013</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Inhibitors of serine proteases, particularly HCV NS3-NS4A protease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2005035525A2?cl=en">WO2005035525A2</a></td><td class="patent-data-table-td patent-date-value">Sep 7, 2004</td><td class="patent-data-table-td patent-date-value">Apr 21, 2005</td><td class="patent-data-table-td ">Vertex Pharma</td><td class="patent-data-table-td ">2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006105374A2?cl=en">WO2006105374A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 30, 2006</td><td class="patent-data-table-td patent-date-value">Oct 5, 2006</td><td class="patent-data-table-td ">Andrew J Carter</td><td class="patent-data-table-td ">Optimizing pharmacodynamics of therapeutic agents for treating vascular tissue</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007016589A2?cl=en">WO2007016589A2</a></td><td class="patent-data-table-td patent-date-value">Aug 1, 2006</td><td class="patent-data-table-td patent-date-value">Mar 29, 2007</td><td class="patent-data-table-td ">Vertex Pharma</td><td class="patent-data-table-td ">Inhibitors of serine proteases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007059221A2?cl=en">WO2007059221A2</a></td><td class="patent-data-table-td patent-date-value">Nov 13, 2006</td><td class="patent-data-table-td patent-date-value">May 24, 2007</td><td class="patent-data-table-td ">Vertex Pharma</td><td class="patent-data-table-td ">Hepatitis c virus variants</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007079260A1?cl=en">WO2007079260A1</a></td><td class="patent-data-table-td patent-date-value">Dec 29, 2006</td><td class="patent-data-table-td patent-date-value">Jul 12, 2007</td><td class="patent-data-table-td ">Gilead Sciences Inc</td><td class="patent-data-table-td ">Methods for improving the pharmacokinetics of hiv integrase inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2008067164A2?cl=en">WO2008067164A2</a></td><td class="patent-data-table-td patent-date-value">Nov 14, 2007</td><td class="patent-data-table-td patent-date-value">Jun 5, 2008</td><td class="patent-data-table-td ">Abbott Lab</td><td class="patent-data-table-td ">Solid pharmaceutical dosage formulations</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010093843A2?cl=en">WO2010093843A2</a></td><td class="patent-data-table-td patent-date-value">Feb 12, 2010</td><td class="patent-data-table-td patent-date-value">Aug 19, 2010</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Hcv combination therapies</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010115981A1?cl=en">WO2010115981A1</a></td><td class="patent-data-table-td patent-date-value">Apr 9, 2010</td><td class="patent-data-table-td patent-date-value">Oct 14, 2010</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">7-azadispiro [3.0.4.1] decane-8-carboxamides as hepatitis c virus inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010116248A1?cl=en">WO2010116248A1</a></td><td class="patent-data-table-td patent-date-value">Apr 9, 2010</td><td class="patent-data-table-td patent-date-value">Oct 14, 2010</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Organic compounds and their uses</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2010122087A1?cl=en">WO2010122087A1</a></td><td class="patent-data-table-td patent-date-value">Apr 22, 2010</td><td class="patent-data-table-td patent-date-value">Oct 28, 2010</td><td class="patent-data-table-td ">F. Hoffmann-La Roche Ag</td><td class="patent-data-table-td ">Methods for improving pharmacokinetics</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011013110A1?cl=en">WO2011013110A1</a></td><td class="patent-data-table-td patent-date-value">Aug 2, 2010</td><td class="patent-data-table-td patent-date-value">Feb 3, 2011</td><td class="patent-data-table-td ">Ranbaxy Laboratories Limited</td><td class="patent-data-table-td ">Unit dosage forms of hiv protease inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011094489A1?cl=en">WO2011094489A1</a></td><td class="patent-data-table-td patent-date-value">Jan 28, 2011</td><td class="patent-data-table-td patent-date-value">Aug 4, 2011</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Therapies for treating hepatitis c virus infection</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012048235A1?cl=en">WO2012048235A1</a></td><td class="patent-data-table-td patent-date-value">Oct 7, 2011</td><td class="patent-data-table-td patent-date-value">Apr 12, 2012</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">Vitamin e formulations of sulfamide ns3 inhibitors</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012109646A1?cl=en">WO2012109646A1</a></td><td class="patent-data-table-td patent-date-value">Feb 13, 2012</td><td class="patent-data-table-td patent-date-value">Aug 16, 2012</td><td class="patent-data-table-td ">Vertex Pharmaceuticals Incorporated</td><td class="patent-data-table-td ">Treatment of hcv in hiv infection patients</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2013080148A1?cl=en">WO2013080148A1</a></td><td class="patent-data-table-td patent-date-value">Nov 28, 2012</td><td class="patent-data-table-td patent-date-value">Jun 6, 2013</td><td class="patent-data-table-td ">Ranbaxy Laboratories Limited</td><td class="patent-data-table-td ">A process for the preparation of solid dispersion of lopinavir and ritonavir</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc435/defs435.htm&usg=AFQjCNFivWgFr8pvtdk7qYLW9R7yxFP7Dg#C435S184000">435/184</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S365000">514/365</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc548/defs548.htm&usg=AFQjCNEJR3l-3fNtZ4E4S53vEr85bVXOrQ#C548S204000">548/204</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc548/defs548.htm&usg=AFQjCNEJR3l-3fNtZ4E4S53vEr85bVXOrQ#C548S205000">548/205</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0217220000">C07D217/22</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0031180000">A61P31/18</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031335000">A61K31/335</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031340000">A61K31/34</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031442700">A61K31/4427</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0401140000">C07D401/14</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031470000">A61K31/47</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0277240000">C07D277/24</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0307200000">C07D307/20</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C08F0002340000">C08F2/34</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031425000">A61K31/425</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031336000">A61K31/336</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031550000">A61K31/55</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031537500">A61K31/5375</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0295080000">C07D295/08</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0243040000">C07D243/04</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0303460000">C07D303/46</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031472000">A61K31/472</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0417120000">C07D417/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031535000">A61K31/535</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0031120000">A61P31/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0295180000">C07D295/18</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031445000">A61K31/445</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031395000">A61K31/395</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031341000">A61K31/341</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038060000">A61K38/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031426000">A61K31/426</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031498000">A61K31/498</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031453000">A61K31/453</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031337000">A61K31/337</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0277280000">C07D277/28</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031440000">A61K31/44</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038050000">A61K38/05</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0038550000">A61K38/55</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031704800">A61K31/7048</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/498">A61K31/498</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/337">A61K31/337</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/395">A61K31/395</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/7048">A61K31/7048</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/426">A61K31/426</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/44">A61K31/44</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/453">A61K31/453</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/06">A61K38/06</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/55">A61K38/55</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/341">A61K31/341</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=nKdOBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K38/05">A61K38/05</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K31/341</span>, <span class="nested-value">A61K38/55</span>, <span class="nested-value">A61K31/453</span>, <span class="nested-value">A61K31/44</span>, <span class="nested-value">A61K31/395</span>, <span class="nested-value">A61K31/7048</span>, <span class="nested-value">A61K38/05</span>, <span class="nested-value">A61K31/337</span>, <span class="nested-value">A61K38/06</span>, <span class="nested-value">A61K31/426</span>, <span class="nested-value">A61K31/498</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">May 28, 2013</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CLAIMS 5, 13, 17 AND 18 ARE CANCELLED.CLAIMS 1-4, 6-12 AND 14-16 ARE DETERMINED TO BE PATENTABLE ASAMENDED.NEW CLAIMS 19-46 ARE ADDED AND DETERMINED TO BE PATENTABLE.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 5, 2013</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ABBVIE INC., ILLINOIS</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20120801</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ABBOTT LABORATORIES;REEL/FRAME:029756/0593</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 24, 2011</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 23, 2010</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20100825</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 20, 2007</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 28, 2003</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Mar 13, 2001</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 23, 1997</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ABBOTT LABORATORIES, ILLINOIS</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:NORBECK, DANIEL W.;KEMPF, DALE J.;LEONARD, JOHN M.;AND OTHERS;REEL/FRAME:008716/0702;SIGNING DATES FROM 19960621 TO 19960626</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_8a2b04e7bf975d5171d8e4c0b6365c7a.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U29DYthlfdOqbiZ8w23R1wwhTpZFQ\u0026id=nKdOBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U1obWuiEi4EJ20d9YEjPNiecdYYrQ\u0026id=nKdOBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U0OOH5kG6YWK7EvAWroiK3IraRv4w","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Method_for_improving_pharmacokinetics.pdf?id=nKdOBAABERAJ\u0026output=pdf\u0026sig=ACfU3U3dvYrdDsUTphOj2jSKEVcWad5NJA"},"sample_url":"http://www.google.com/patents/reader?id=nKdOBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>